ArticleAnnals of thoracic surgery short reports2025
National Trends in Mitral Valve Surgery Outcomes in Centers With and Without Mitral Transcatheter Edge-to-Edge Repair.
Article in Annals of thoracic surgery short reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Valve guidelines recommend mitral valve transcatheter edge-to-edge repair (M-TEER) be offered at comprehensive valve centers along with complex mitral valve surgery (MVS). We evaluated mitral valve surgery (MVS) outcomes based on center availability of M-TEER on a national scale. Methods: The National Readmissions Database was used to review adult patients who underwent MVS at centers with and without M-TEER from 2016 to 2020. Patients with a history of endocarditis or prosthetic valve dysfunction were excluded. The primary outcome was 30-day mortality. Multivariable logistic regression analysis was conducted to determine the effect of M-TEER availability on postoperative mortality. Results: Of the 50,179 patients who underwent MVS from 2016 to 2020, 15,485 underwent MVS at a non-M-TEER hospital. During this period, the number of centers with M-TEER significantly increased from 2539 in 2016 to 6326 in 2020 ( Conclusions: Centers with M-TEER have significantly lower 30-day mortality after MVS than centers without M-TEER. This study supports the concept of a comprehensive valve center in the treatment of mitral valve disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.